Jeff Cambra
CEO

SpinaFX develops minimally invasive, image-guided therapy for patients suffering from contained lumbar herniated discs. The company's core treatment involves the intravertebral injection of an oxygen-ozone gas mixture to address radiculopathy. This approach aims to provide rapid and sustained pain relief as an alternative to conservative care or surgery.
Raised to date
$9.1MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CEO
Many patients with contained herniated discs experience back pain that does not respond to conservative treatments, yet they may not be ideal candidates for traditional surgical interventions like discectomy. This creates a therapeutic gap, leaving patients with limited options for effective and less invasive pain relief.
SpinaFX Medical aims to fill the therapeutic gap in back pain treatment with Triojection, a minimally invasive, image-guided therapy for contained herniated discs. The Triojection system delivers a precise mixture of oxygen and ozone gas into the affected disc, reducing disc volume and related nerve pressure. This outpatient procedure is designed to provide rapid and sustained relief from back and leg pain, offering a less invasive alternative to surgery. The system consists of a computer-controlled console and a disposable single-use syringe with an ozone generation chamber, ensuring a sterile, metered, and accurate concentration of O2/O3 at the point of care.
The primary target audience includes patients with contained herniated discs experiencing back and leg pain who have not responded to conservative therapies, as well as physicians and facilities seeking minimally invasive treatment options.